Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

计划入组 136 人 · 首次发布于 2020 年 2 月 18 日

Safety and Effectiveness Trial of the Ventana Fenestrated Stent Graft System

计划入组 76 人 · 首次发布于 2011 年 12 月 14 日

FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

计划入组 12 人 · 首次发布于 2024 年 9 月 24 日

MB-CART FolR1

FOLR1 targeting CAR-T(Miltenyi Biotec)

anti-FOLR1/anti-SLC34A2 bispecific monoclonal antibody drug conjugate (cancer)

Pentana Solutions B.V.

Netherlands

GENTINA THIBAUT

France

Sentara Hospitals

United States

Roche's VENTANA FOLR1 RxDx Assay Receives CE Mark for Ovarian Cancer Treatment Selection

Roche's VENTANA FOLR1 RxDx Assay Receives CE Mark for Ovarian Cancer Diagnosis

European Commission Approves AbbVie's Elahere for Platinum-Resistant Ovarian Cancer